Vaccines Bioprocess Development and Commercialisation
Discover vaccine development, commercialisation and regulatory requirements.
Updated Events for 2013 and 2014
We are delighted to announce that this vaccine course will be internationalised due to increasing demand and will have two future presentations in India in 2013 and Portugal in 2014.
As announced at the 23rd ESACT meeting in Lille, University College London in collaboration with the Instituto de Biológia Experimental Tecnológica (iBET) is announcing its Vaccine Development course for 14th-16th April 2014.
Vaccines represent a challenging area of development. There are many antigen designs and expression systems, all of which impact on the upstream and downstream process steps. This course seeks to use a combination of lectures and case studies to allow delegates to appreciate the different scale-up strategies within the complex regulatory framework for these multifarious biologics.
A team of outstanding international experts has agreed to join us in exploring the issues related to process development, regulation and commercialization of new vaccine products. The speakers will be available during for course for direct discussion and networking opportunities.
Speakers from MedImmune, CSL, Pfizer, Protein Sciences, GE Healthcare and GSK will focus on the key technical aspects critical for success and integrate those with an understanding of the regulatory environment.
The provisional programme is as follows.
- Development of a Penta-valent vaccine and getting WHO certification (Martin Reers, Biological E Pvt Ltd)
- Process Development and Regulation of Recombinant Vaccines (Barry Buckland, BioLogicB)
- Advanced Analytics for Vaccine Characterisation (Indresh Srivastava, Protein Sciences Corp)
- Formulation and evading the Cold Chain (Jeff Drew, Stabilitech Ltd)
- Virus vaccine production – strategies and methodologies (Manuel Carrondo, iBET)
- Scale Down Models for Vaccine Development (Tarit Mukhopadhyay UCL)
- Modern Adjuvants (Debbie Drane, CSL)
- QbD in Vaccine Development (Ann-Kristin Gellerbring)
- Single use technology economics for Vaccine Processing (Ingrid Long, GE Healthcare)
- Case Study 1 – Vaccine Project Management on LIAV Influenza vaccine (Mark Proctor, MedImmune)
- Facilities of the Future (Alain Pralong, GSK)
- Quality Control of Vaccines (Martin Wisher, Bioreliance)
- Polysaccharide and Conjugate Vaccine Development (Steve Kolodziej, Pfizer)
- Case Study 2 - Process Development (Paula Alves, iBET)
- A networking dinner is included on the first night.
This meeting will be located at iBET, Oeiras, Portugal. The closest airport is Lisbon Portela Airport and is a short 30 minute drive to the meeting location.
ESACT Sponsorship and Student Support
The European Society of Animal Cell Technology has kindly agreed to sponsor 5 students to attend this meeting. The sponsor amount covers the cost of registration only. It does not include travel to Oeiras, Portugal. Any student, irrespective of nationality, is eligible to apply. Applicants must be in full time education engaged in a doctoral level degree programme.
Closing date 30th March.
To apply, please fill in the online form.
- London - 5th-7th December, 2012
- India - 23rd-25th September, 2013
- Portugal - 14th-16th April, 2014 at iBET
- USA - 23rd-25th June, 2015 at MIT
Supported by the European Society for Animal Cell Technology
Who should attend?
- Specialised vaccines staff who would benefit from broadening their knowledge base
- Those new to vaccine development (recent graduates / research scientists)
- Project Managers, funders and policy-makers wanting to gain an understanding in vaccines.
Questions? E-mail email@example.com for further information.
Download the flyer for the course here.
Page last modified on 18 sep 13 14:29